<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576341</url>
  </required_header>
  <id_info>
    <org_study_id>HX575-308</org_study_id>
    <secondary_id>2011-002871-40</secondary_id>
    <nct_id>NCT01576341</nct_id>
  </id_info>
  <brief_title>HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)</brief_title>
  <acronym>SENSE</acronym>
  <official_title>Open Label, Single Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of HX575 Epoetin Alfa in the Treatment of Anemia Associated With Chronic Kidney Disease in Pre-dialysis and Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the immunogenicity, safety, and efficacy of HX575 epoetin alfa
      administered subcutaneously (s.c.) in patients suffering from anemia due to chronic kidney
      disease (CKD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Erythropoietin (EPO) Antibodies</measure>
    <time_frame>52 weeks</time_frame>
    <description>The incidence of antibody formation against epoetin in Radio-immuno-precipitation (RIP) assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level and Change From Baseline Period at Visit 16 (End of Study)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Actual values of hemoglobin levels at end of study visit and change from Baseline Period (Week -4 to Week -1)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">417</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>HX575 epoetin alfa (Sandoz)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HX575 epoetin alfa (Sandoz)</intervention_name>
    <description>Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.</description>
    <arm_group_label>HX575 epoetin alfa (Sandoz)</arm_group_label>
    <other_name>Binocrit®, Epoetin alfa HEXAL®, Novicrit®, Abseamed®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Adult male and female patients w or w/o dialysis treatment

          -  Stable i.v. or s.c. maintenance therapy with an EU-approved ESA treatment or ESA
             naïve.

          -  Adequate iron substitution

        Main Exclusion Criteria:

          -  History of Pure Red Cell Aplasia (PRCA) or anti-erythropoietin (EPO) antibodies

          -  Contraindications for ESA therapy

          -  Serum albumin &lt; 3.0 g/dL

          -  Immunocompromized patients (immunosuppressive treatment, chemotherapy)

          -  Hepatitis C infection on an active treatment or hepatitis B or human immunodeficiency
             virus (HIV) infection

          -  Systemic lupus erythematosus

          -  Symptomatic congestive heart failure, Unstable angina pectoris, or myocardial
             infarction within 6 months

          -  History of malignancy of any organ system within the last 5 years

          -  History of use of any non-EU approved ESA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandoz Biopharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Sandoz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Homberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Nettetal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Czestochowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Olkusz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Plock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Wadowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Warzawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Lasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Kolomna</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Mytischi</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Podolsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Yekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chernovtsy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Lugansk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Nikolaev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Ternopil</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Zaporizhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Zhitomyr</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <results_first_submitted>April 3, 2017</results_first_submitted>
  <results_first_submitted_qc>April 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2017</results_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epoetin alfa, ESA, HX575, CKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients, suffering from anemia associated with chronic Kidney Disease (CKD), were treated s.c. with HX575 at least once per week in order to achieve and maintain Hb concentration within the target range of 10.0 to 12.0 g/dL. 417 patients were enrolled.</recruitment_details>
      <pre_assignment_details>Male and female patients (ESA [Erythropoiesis Stimulating Agent]-naïve/on ESA-maintenance therapy, i.v./s.c.) aged 18 years/older, suffering from anemia assoc. with CKD, with/without dialysis treatment. Anemia: Mean Hb conc. &lt;= 11.0 g/dL for ESA naïve, 9.0-12.0 g/dL for patients receiving ESA therapy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HX575, Safety Population</title>
          <description>In the single arm study, HX575 was tested as investigational medicinal product. The single arm includes ESA-naïve patients and patients on ESA-maintenance therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="417"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="324"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Kidney transplantation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population: The safety population consists of all patients that received at least one dose of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>HX575, Safety Population</title>
          <description>The Study was designed as single arm study with HX575 tested as investigational medicinal product. The safety population (SAF) consisted of all patients that received at least one dose of study drug. 417 patients enrolled, 416 treated. Group includes ESA-naïve patients and patients on ESA-maintenance therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="416"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="15.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="416"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.9" spread="9.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.6" spread="15.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.26" spread="5.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ESA pre-treatment</title>
          <description>A patient is considered to be ESA naïve if the patient did not receive any ESA therapy within 2 months prior to first screening visit.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ESA naive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESA maintenance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-Erythropoietin (EPO) Antibodies</title>
        <description>The incidence of antibody formation against epoetin in Radio-immuno-precipitation (RIP) assay</description>
        <time_frame>52 weeks</time_frame>
        <population>Safety population: The safety population consists of all patients that received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>HX575</title>
            <description>HX575 administered s.c. at least once per week. During the treatment period the dose was individually titrated to maintain hemoglobin levels between 10.0 and 12.0 g/dL</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Erythropoietin (EPO) Antibodies</title>
          <description>The incidence of antibody formation against epoetin in Radio-immuno-precipitation (RIP) assay</description>
          <population>Safety population: The safety population consists of all patients that received at least one dose of study drug</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.7" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Incidence rate</param_type>
            <param_value>0.019</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Incidence rate is based on duration of treatment period (years)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Level and Change From Baseline Period at Visit 16 (End of Study)</title>
        <description>Actual values of hemoglobin levels at end of study visit and change from Baseline Period (Week -4 to Week -1)</description>
        <time_frame>52 weeks</time_frame>
        <population>Per-protocol population (all patients that received at least one dose of study drug) with non-missing Hemoglobin value at Visit 16 (end of study).</population>
        <group_list>
          <group group_id="O1">
            <title>HX575 - ESA Naive</title>
            <description>HX575 administered s.c. at least once per week. During the treatment period the dose was individually titrated to maintain hemoglobin levels between 10.0 and 12.0 g/dL. At study start patients were either ESA (Erythropoiesis Stimulating Agent) naive or on ESA maintenance treatment. This group only contains patients that were ESA naive at study start, e.g. did not receive any ESA dose within 2 months prior to first screening visit.</description>
          </group>
          <group group_id="O2">
            <title>HX575 - ESA Maintenance</title>
            <description>HX575 administered s.c. at least once per week. During the treatment period the dose was individually titrated to maintain hemoglobin levels between 10.0 and 12.0 g/dL. At study start patients were either ESA (Erythropoiesis Stimulating Agent) naive or on ESA maintenance treatment. This group only contains patients that were on ESA maintenance treatment at study start, e.g. did receive at least one dose of commercial ESA treatment within 2 months prior to first screening visit.</description>
          </group>
          <group group_id="O3">
            <title>HX575</title>
            <description>HX575 administered s.c. at least once per week. During the treatment period the dose was individually titrated to maintain hemoglobin levels between 10.0 and 12.0 g/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Level and Change From Baseline Period at Visit 16 (End of Study)</title>
          <description>Actual values of hemoglobin levels at end of study visit and change from Baseline Period (Week -4 to Week -1)</description>
          <population>Per-protocol population (all patients that received at least one dose of study drug) with non-missing Hemoglobin value at Visit 16 (end of study).</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Actual Value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.81" spread="1.336"/>
                    <measurement group_id="O2" value="10.86" spread="1.060"/>
                    <measurement group_id="O3" value="10.83" spread="1.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="1.601"/>
                    <measurement group_id="O2" value="0.22" spread="1.223"/>
                    <measurement group_id="O3" value="1.02" spread="1.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks (screening period) + 52 weeks (treatment period)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HX575, Safety Population</title>
          <description>Study was designed as single arm study with HX575 tested as investigational medicinal product. Safety population includes ESA therapy naïve patients and ESA maintenance patients. Shown are all AEs including non-treatment related AEs.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Carditis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal mass</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism secondary</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Calcinosis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute hepatitis b</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Shunt occlusion</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemangioma</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Glioma</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Uraemic encephalopathy</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="42" subjects_affected="39" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>† A</description>
                <counts group_id="E1" events="75" subjects_affected="42" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor shall have the right to the first publication or presentation of the results of the study which is intended to be a joint, multi-center publication of the study results. Following the first publication, institutions and/or Principal Investigators may publish or present data or results from the study per the terms of the clinical trial agreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biopharmaceutical Clinical Development, Strategic Planning</name_or_title>
      <organization>Sandoz</organization>
      <phone>0049 80244760</phone>
      <email>biopharma.clinicaltrials@sandoz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

